Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
Survodutide28 residuesHQGTFTSDYSKYLDERAAKDFIKWLESAEach bubble = one amino acid. Size = residue mass. Color = chemical class.Survodutide is a dual GLP-1/glucagon agonist with Phase 2 data showing 80% liver fat reduction and 18.7% weight loss. Currently in Phase 3 trials for MASH and obesity. Not yet FDA-approved; Boehringer Ingelheim Phase 3 results pending in 2026 or 2027.
600mcg · Weekly
Summary: Add 2mL BAC water to your 10mg vial. Draw to 12.0 units on a U-100 syringe for a 600mcg dose. This vial will last 16 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 600mcg | Weekly |
| Moderate | 2,400mcg | Weekly |
| Aggressive | 4,800mcg | Weekly |
Survodutide requires a 10 mg vial and 2 mL bacteriostatic water for reconstitution. That gives you 5 mg/mL, or 5,000 mcg/mL. On a standard U-100 insulin syringe, each unit equals 50 mcg. So 0.6 mg (the starting dose) is 12 units. The 1.2 mg escalation dose is 24 units. At the full 4.8 mg MASH target, you're drawing 96 units. The thing most people miss about survodutide is the escalation timeline. You're looking at 40 weeks of dose escalation before reaching therapeutic range. That's nearly 10 months. The clinical trials built this in deliberately because the GI burden is dose-dependent; skipping steps causes severe nausea and vomiting. If you need to pause dosing for more than 2 weeks, restart from 0.6 mg and re-titrate. That's the clinical trial protocol, not optional caution. Store reconstituted vials at 2 to 8 degrees Celsius and use within 4 weeks.
Dosing based on SYNCHRONIZE Phase 3 Trial: survodutide in adults with MASH and fibrosis — 9 published references.View all sources →
Cross-check your Survodutide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Survodutide is a dual GLP-1/glucagon agonist with Phase 2 data showing 80% liver fat reduction and 18.7% weight loss. Currently in Phase 3 trials for MASH and obesity. Not yet FDA-approved; Boehringer Ingelheim Phase 3 results pending in 2026 or 2027.
